Claus Elizabeth B, Black Peter M, Bondy Melissa L, Calvocoressi Lisa, Schildkraut Joellen M, Wiemels Joseph L, Wrensch Margaret
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut, USA.
Cancer. 2007 Aug 1;110(3):471-6. doi: 10.1002/cncr.22783.
The decision to commence or continue use of hormone replacement therapy or oral contraceptives in women presumed or known to be diagnosed with intracranial meningioma is a common clinical question in neurosurgery. A review of the English-language literature was undertaken to examine the association between the use of exogenous hormones and meningioma risk. Seven publications were identified, 6 of which met criteria for inclusion. No randomized clinical trial data were available, hence, results were collected from 2 population-based case-control studies, 2 hospital-based case-control studies, 1 nested case-control study drawn from a large national cohort, and 1 retrospective cohort study. At present, there is no statistical evidence of an increased risk of meningioma among users of oral contraceptives. Although not definitive, available data suggest an association between the use of hormone replacement therapy and increased meningioma risk. Further evaluation of exogenous hormone use in women with meningioma is needed with particular attention to stratification by hormone (ie, estrogen and/or progesterone) composition, duration of and age at use as well as tumor receptor subtype.
对于疑似或已知患有颅内脑膜瘤的女性，决定开始或继续使用激素替代疗法或口服避孕药是神经外科常见的临床问题。我们对英文文献进行了综述，以研究外源性激素的使用与脑膜瘤风险之间的关联。共确定了7篇出版物，其中6篇符合纳入标准。由于没有随机临床试验数据，因此我们从2项基于人群的病例对照研究、2项基于医院的病例对照研究、1项从大型全国队列中抽取的巢式病例对照研究以及1项回顾性队列研究中收集了结果。目前，尚无统计学证据表明口服避孕药使用者患脑膜瘤的风险增加。虽然尚无定论，但现有数据表明激素替代疗法的使用与脑膜瘤风险增加之间存在关联。需要对脑膜瘤女性患者使用外源性激素的情况进行进一步评估，尤其要注意按激素（即雌激素和/或孕激素）成分、使用时间和年龄以及肿瘤受体亚型进行分层。
